nach oben

Erschienen in:

01.05.2020 | News item

Rivaroxaban contraindicated in patients with prosthetic heart valves

Erschienen in: Reactions Weekly | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Auszug

Thromboprophylaxis with rivaroxaban (Xarelto) is contraindicated in patients who have undergone transcatheter aortic valve replacement (TAVR), notes Ireland's Health Products Regulatory Authority (HPRA) in a recent communication. …

Health Products Regulatory Authority. Rivaroxaban (Xarelto) - not for use as thromboprophylaxis in patients who have recently undergone transcatheter aortic valve replacement. Internet Document : 22 Apr 2020. Available from: URL: https://www.hpra.ie/docs/default-source/publications-forms/newsletters/hpra-drug-safety-newsletter-edition-96.pdf?sfvrsn=5

Titel: Rivaroxaban contraindicated in patients with prosthetic heart valves
Publikationsdatum: 01.05.2020
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2020
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-020-78199-3

Springer Medizin

Rivaroxaban contraindicated in patients with prosthetic heart valves

Auszug

Weitere Artikel der Ausgabe 1/2020

Fingolimod

Clinical simulations cost effective in reducing medication errors

Warfarin overdose

Ibrutinib

Prednisolone

Ramipril

Springer Medizin

Auszug

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Fingolimod

Clinical simulations cost effective in reducing medication errors

Warfarin overdose

Ibrutinib

Prednisolone

Ramipril